F. Rocha

发表

Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures

E. Ben-Menachem, A. Biraben, S. Benbadis, 2018, Epilepsy & Behavior.

Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of Neurological Sciences.

Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience

E. Tolosa, W. Poewe, O. Rascol, 2019, Journal of Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline mao-b inhibitors use: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Influence of baseline off-time in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II

H. Reichmann, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials

W. Poewe, O. Rascol, R. Hauser, 2019, Journal of the Neurological Sciences.

Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience

W. Poewe, O. Rascol, A. Lees, 2019, Journal of the Neurological Sciences.

Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data

W. Poewe, O. Rascol, A. Lees, 2019, Journal of Neurological Sciences.

Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II

H. Reichmann, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Switching entacapone ‘non-responders’ to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study

W. Poewe, O. Rascol, A. Lees, 2019, Journal of the Neurological Sciences.

Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg

W. Poewe, O. Rascol, A. Lees, 2019, Journal of Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg

E. Tolosa, A. Lees, J. Ferreira, 2019, Journal of Neurological Sciences.

Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II

H. Reichmann, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II

W. Poewe, O. Rascol, A. Lees, 2019, Journal of the Neurological Sciences.

Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II

E. Tolosa, W. Poewe, O. Rascol, 2019, Journal of the Neurological Sciences.

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials

S. Benbadis, D. Blum, Hailong Cheng, 2017, Epilepsia open.

Absorption, metabolism and excretion of opicapone in human healthy volunteers

L. Kiss, P. Soares-da-Silva, M. Bonifácio, 2022, British journal of clinical pharmacology.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures

S. Jóźwiak, P. Veggiotti, P. Soares-da-Silva, 2018, Epilepsy & Behavior.

Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy

Michael C. Smith, E. Trinka, D. Vossler, 2019, Epilepsia.

Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures

P. Ryvlin, B. Abou-Khalil, D. Blum, 2018, Epilepsy Research.

Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate

J. Cramer, P. Ryvlin, F. Gilliam, 2015, Epilepsy & Behavior.

Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18–59 years) adults

E. Ben-Menachem, F. Cendes, W. Rosenfeld, 2020, Epilepsy Research.

Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures

E. Ben-Menachem, A. Biraben, S. Benbadis, 2018, Epilepsy & Behavior.